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Articles

Global burden of maternal and congenital syphilis in 2008
and 2012: a health systems modelling study
N Saman Wijesooriya, Roger W Rochat, Mary L Kamb, Prasad Turlapati, Marleen Temmerman, Nathalie Broutet, Lori M Newman

Summary
Background In 2007, WHO launched a global initiative for the elimination of mother-to-child transmission of syphilis
(congenital syphilis). An important aspect of the initiative is strengthening surveillance to monitor progress towards
elimination. In 2008, using a health systems model with country data inputs, WHO estimated that 1·4 million
maternal syphilis infections caused 520 000 adverse pregnancy outcomes. To assess progress, we updated the 2008
estimates and estimated the 2012 global prevalence and cases of maternal and congenital syphilis.
Methods We used a health systems model approved by the Child Health Epidemiology Reference Group. WHO and
UN databases provided inputs on livebirths, antenatal care coverage, and syphilis testing, seropositivity, and treatment
in antenatal care. For 2012 estimates, we used data collected between 2009 and 2012. We updated the 2008 estimates
using data collected between 2000 and 2008, compared these with 2012 estimates using data collected between 2009
and 2012, and performed subanalyses to validate results.
Findings In 2012, an estimated 930 000 maternal syphilis infections caused 350 000 adverse pregnancy outcomes
including 143 000 early fetal deaths and stillbirths, 62 000 neonatal deaths, 44 000 preterm or low weight births, and
102 000 infected infants worldwide. Nearly 80% of adverse outcomes (274 000) occurred in women who received
antenatal care at least once. Comparing the updated 2008 estimates with the 2012 estimates, maternal syphilis
decreased by 38% (from 1 488 394 cases in 2008 to 927 936 cases in 2012) and congenital syphilis decreased by 39%
(from 576 784 to 350 915). India represented 65% of the decrease. Analysis excluding India still showed an 18%
decrease in maternal and congenital cases of syphilis worldwide.
Interpretation Maternal and congenital syphilis decreased worldwide from 2008 to 2012, which suggests progress
towards the elimination of mother-to-child transmission of syphilis. Nonetheless, maternal syphilis caused substantial
adverse pregnancy outcomes, even in women receiving antenatal care. Improved access to quality antenatal care,
including syphilis testing and treatment, and robust data are all important for achieving the elimination of mother-tochild transmission of syphilis.
Funding The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and
Research Training in Human Reproduction in WHO, and the US Centers for Disease Control and Prevention.
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Introduction
As a public health intervention, antenatal syphilis
Syphilis, a bacterial infection caused by the spirochete screening and treatment is cost-saving in moderate and
Treponema pallidum, can be transmitted sexually or from high prevalence settings, and cost-eﬀective even when
mother to child in utero. Untreated primary or secondary prevalence is less than 1%.7–10
syphilis infections can induce catastrophic fetal outcomes
Unfortunately, congenital syphilis is much harder to
in the second or third trimesters of pregnancy.1 Most diagnose than syphilis in pregnant women, and therefore
maternal syphilis infections are latent (asymptomatic), estimates are needed to accurately reﬂect burden of
but still result in poor pregnancy outcomes in more than disease in most countries. Global maternal and congenital
50% of cases.2–5 Syphilis-associated adverse pregnancy syphilis estimates were published in 2007 using peeroutcomes (ie, congenital syphilis) include early fetal reviewed and unpublished country reports available from
death, stillbirth, preterm birth, low birthweight, neonatal 31 countries from 1997 to 2003 in which studies used
serologically conﬁrmed tests in antenatal care attendees.
death, and congenital infection in infants.
A combination of serological tests measuring infection The 2007 estimates suggested that more than 2 million
activity and conﬁrming exposure to T pallidum can detect maternal and 1·5 million congenital syphilis cases would
asymptomatic syphilis infections in pregnant women. occur every year worldwide without treatment.11 These
Maternal syphilis screening and treatment of seropositive estimates served as the basis for the 2007 launch of a
women with at least 2·4 million units of benzathine global initiative for the elimination of mother-to-child
penicillin prevents most adverse pregnancy outcomes if transmission of syphilis and congenital syphilis, which
provided suﬃciently early (ie, >30 days before delivery).6 has resulted in worldwide policy and programme changes.
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Research in context
Evidence before this study
In 2007, WHO launched the global Elimination of Congenital
Syphilis initiative, with a goal of reducing mother-to-child
transmission of syphilis to a suﬃciently low level that congenital
syphilis was no longer a public health problem. The goal is for
countries to achieve a congenital syphilis rate of 50 or fewer cases
per 100 000 livebirths through achieving programmatic targets
of more than 95% syphilis screening coverage in pregnancy and
more than 95% treatment of seropositive women. In 2008,
surveillance of syphilis in pregnancy was included within the HIV
Universal Access and Global AIDS Response Progress Reporting
(UA/GARPR) system. Countries were encouraged to report data
for three core indicators collected on antenatal care attendees:
syphilis testing, seropositivity, and treatment. Baseline global and
regional estimates of syphilis in pregnancy for 2008, which used
antenatal syphilis seropositivity data reported by 96 countries to
the UA/GARPR, found 1·4 million maternal and
520 000 congenital syphilis infections globally, including
304 000 perinatal deaths. In this analysis, we used the most
recently collected GARPR data (2009–12) for key congenital
syphilis indicators for 2012 estimates, and compared these
against 2008 updated baseline data from GARPR (2000–08),
the start of the elimination eﬀort.
Added value of this study
The ﬁndings of our current analysis add value to the existing
body of evidence by providing a 5-year, interim report on

In 2008, the WHO and global partners introduced
surveillance of syphilis in pregnancy within the HIV
Universal Access and Global AIDS Response Progress
Reporting (UA/GARPR) system to monitor progress.
Countries were encouraged to report data for three core
indicators collected on antenatal care attendees: syphilis
testing, seropositivity, and treatment (added in 2010).12
To measure progress for the new initiative, the 2008
baseline global and regional estimates of syphilis in
pregnancy used antenatal syphilis seropositivity data
reported by 96 countries to the UA/GARPR. These
2008 estimates noted 1·4 million maternal and
520 000 congenital syphilis infections, including
304 000 perinatal deaths, occurred globally.13 The 2008
estimates uniformly adjusted for seropositivity to
minimise overdiagnosis of active syphilis. Furthermore,
the 2008 estimates used ﬁxed regional assumptions for
testing and treatment coverage.
We aimed to estimate the global and regional cases
and prevalence of maternal and congenital syphilis in
2012. With stronger surveillance and better countrylevel reporting over time, we also used the same method
to revise the 2008 (baseline) estimates, and compared
these updated 2008 estimates with the new 2012
estimates to assess progress made in the global
elimination initiative.
e526

progress made with the launch of the global initiative for the
elimination of congenital syphilis. The analysis found a
38% reduction in the number of pregnant women with
syphilis and in the number of congenital syphilis cases.
Global monitoring improved from 2008 to 2012, with more
countries reporting on sexually transmitted infection
indicators. Nonetheless, certain countries experienced
challenges and may need support. Updated estimates of the
baseline global burden of maternal and congenital syphilis
(2008) using GARPR data were available for more countries.
The study presents an acceptable model vetted by experts for
estimating progress on the global elimination of congenital
syphilis initiative for use in future updates.
Implications of all the available evidence
These results help policy makers and leaders understand
where challenges remain and can be addressed. They can be
used for broader global maternal and child health
programmes, in which the extent of congenital syphilis (still
accounting for almost 200 000 perinatal deaths each year) is
often overlooked. Regions and countries can use our data to
advocate for the needed resources to carry out routine
screening of syphilis in antenatal care in all countries,
including some newer screening applications such as dual
rapid HIV and syphilis tests on a single device, and to estimate
treatment needs.

Methods
Data inputs
In this analysis we used a health systems model
approved by the Child Health Epidemiology Reference
Group in June, 2011, and by technical experts at the
WHO meeting on sexually transmitted infection
estimates held in November, 2013. Whenever possible,
we used actual country data reported by the 194 WHO
member states and where data were not available, we
imputed numbers based on regional estimates
(appendix); where no data were available for southern
Latin America, we used the regional mean for tropical
Latin America; where no data were available for highincome North America, Australasia, or high-income
Asia Paciﬁc, we used the regional mean for western
Europe; where no data were available for east Asia, we
used the regional mean for southeast Asia. For each
country, we obtained the numbers of livebirths
from the United Nations Development Programme
World Population Prospects database.14 Cousens and
colleagues15 provided the estimated national numbers
of stillbirths (deﬁned as fetal death in the third
trimester, with fetal weight at least 1000 g or gestation
at least 28 completed weeks).
We obtained antenatal clinic attendance (at least one
visit) from the WHO Global Health Observatory.16
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We used most recently collected UA/GARPR data from
2000–08 for updated 2008 and 2009–12 for 2012
estimates. The UA/GARPR provided country data for
three variables: syphilis seropositivity with speciﬁed test
type (non-treponemal, treponemal, or both), testing of
antenatal care attendees for syphilis, and treatment of
syphilis seropositive antenatal care attendees. When
seropositivity data were unavailable, we searched
PubMed for peer-reviewed reports and the grey literature
between Jan 1, 2000, and March 18, 2014, using the search
terms (“syphilis” OR “treponemal” OR “non-treponemal”
AND “[country name]” and added [“pregnant” OR
“perinatal” OR “antenatal”]. This search provided
seropositivity data for eight countries.17–24 For updated
2008 estimates, we used the testing data with the
treatment assumption used for the original 2008
estimates.13 When data were unavailable for these
variables, we used the most recent country values to
calculate regional means for 21 Institute for Health
Metrics and Evaluation (IHME) regions for imputation.
IHME regions categorise countries based on
epidemiological similarity and geographical proximity.25
However, we presented these data for the six WHO
regional groupings to facilitate WHO regional
programmatic and planning processes.
The appendix shows the model input values and
regional means by WHO and IHME regions used to
generate the updated 2008 and 2012 estimates. We used
the following assumptions based on published scientiﬁc
literature to generate estimates: ﬁrst, we deﬁned probable
active syphilis infections as cases reactive on both
treponemal and non-treponemal serological tests. We
applied separate correction factors for four diﬀerent
scenarios by the country-speciﬁed test type to adjust for
possible error due to the diagnostic test type used: both
reactive non-treponemal and reactive tests (1·0);
only reactive non-treponemal (0·522); only reactive
treponemal tests (0·536); and neither test reported
(0·686; appendix). This correction factor was based on a
random eﬀects modelling analysis of positivity data
obtained through a recent review of the scientiﬁc
literature.26
Second, the number of early fetal deaths (deﬁned as
occurring at 22 through 28 weeks’ gestation) was
estimated at 20% of stillbirths based on the relationship
of early to late fetal deaths recorded in multicountry
reviews (mainly high-income countries).15,27,28 We
estimated the number of pregnancies by summing
livebirths, stillbirths, and early fetal deaths.
Third, the expected proportions of pregnancies
resulting in any adverse pregnancy outcomes (52%)
included early fetal deaths or stillbirths (21%), preterm
(born alive before 37 weeks’ gestation) or low birthweights
(weighing <2500 g; 6%), neonatal death (death in ﬁrst
28 days; 9%, or clinical disease in infants (29–365 days;
16%, of syphilis-infected women and were based on a
recent meta-analysis.3

Finally, the eﬀectiveness of penicillin at preventing any
adverse pregnancy outcome (84%, the weighted average
using the expected proportions as the weights) included
early fetal deaths or stillbirths (82%), preterm or low
birthweights (64%;, neonatal deaths (80%, and clinical
disease in infants (97%, and was based on a published
literature review.6
In sum, this method for updated 2008 and
2012 estimates was identical to the health systems model
used for the original WHO 2008 estimates except that it
used newly available, country-reported testing data and
country-reported treatment data (2012 only); a more
nuanced, evidence-based correction factor for test type;
and IHME regional classiﬁcations for imputing means
rather than medians for countries without data.13

Analyses
We used a four-step process to estimate for 2012, and
update for 2008, the number of pregnant women with
probable active syphilis infections and associated adverse
pregnancy outcomes for each country. We summed
country values to N, where N equals the number of
countries for each of the six WHO regions and 194 WHO
member countries for the global total.
For step 1 we estimated the number of pregnant
women with probable active syphilis infections.

See Online for appendix

N

ΣPASI , where PASI

c=1

c

c

= (Posc)(cfc)(pregc)

In step 2 we estimated the number of pregnant women
with probable active syphilis infections attending
antenatal care;
N

ΣPASI_ANC , where PASI_ANC =(PASI )(ANC1 )
c

c

c

c

c=1

among antenatal care attendees, we estimated the
numbers of pregnant women with syphilis infections
who were not tested; tested but not treated; and tested
and treated for syphilis:
N

Σ PASI_ANC_NT , where PASI_ANC_NT
c

c

=

c=1

(PASI_ANCc)(1–Testedc)
N

Σ PASI_ANC_TNT , where PASI_ANC_TNT
c

c

=

c=1

(PASI_ANCc)(Testedc)(1–Treatedc)
N

ΣPASI_ANC_TT , wherePASI_ANCTT =
c

c

c=1

(PASI_ANCc)(Testedc)(Treatedc)

N

ΣPASI_ANC_TT ,
c

c=1

where PASI_ANC_TTc = (PASI_ANCc)(Testedc)(Treatedc)
N

ΣPASI_ANC_TNT , wherePASI_ANC_TNT
c

c

=

c=1

(PASI_ANCc)(Testedc)(1–Treatedc)
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N

And for pregnant women with syphilis who did not
access antenatal care services.
N

ΣPASI_NOANC , where PASI_NOANC =
c

c=1

(PASIc) (1 – ANC1c)
In step 3, we estimated the numbers of adverse
pregnancy outcomes for syphilis-infected pregnant
women attending antenatal care who were not tested;
tested but not treated; and tested and treated but in
whom treatment was ineﬀective at preventing an adverse
pregnancy outcome:
c

c=1

c

=

(PASI_ANC_NTc) (PEFD,SB + PP,LBW + PNND + PI)
N

ΣAO_ANC_TNT , where AO_ANC_TNT
c

c=1

c

=

(PASI_ANC_TNTc) (PEFD,SB + PP,LBW + PNND + PI)
N

ΣAO_ANC_TT , where AO_ANC_TT
c

c=1

c

=

(PASI_ANC_TTc) ((PEFD,SB) (((PEFD,SB) (1 – EEFD,SB)) +

((PP,LBW) (1 – EP,LBW)) + (1 – ENND)) + ((PI)(1 – EI)))
And for pregnant women with syphilis who did not
access antenatal care services:

Estimated number of adverse pregnancy outcomes

250 000

African region
Eastern Mediterranean region
Region of the Americas
Western Pacific region
European region
Southeast Asia region

200 000

150 000

100 000

c

c

=

(PASI_NOANCc)(PEFD,SB + PP,LBW + PNND+ PI)
For step 4, for the total number of adverse outcomes
associated with syphilis in pregnancy, we summed
adverse outcomes among women who did not attend
antenatal care and antenatal care attendees who were not
tested, tested but not treated, and tested and treated for
syphilis:
N

ΣAO, where AO

c=1

c

=AO_NOANCc + AO_ANC_NTc +

To calculate maternal and congenital syphilis
prevalence, we divided the respective case estimates by
the estimated number of pregnancies.
For analytical purposes, we calculated the percent
change between updated 2008 and 2012 estimates
worldwide, for six WHO regions, and 194 countries to
examine which countries were driving the global change.
To assess robustness of trends in the number of
pregnant women with active syphilis infections from the
updated 2008 to 2012 estimates, we did two additional
analyses: all countries, irrespective of whether data were
reported values or regional means (to compare the overall
diﬀerences between estimates); and only countries with
seropositivity values in both updated 2008 and
2012 estimates (to assess trends in consistently reporting
countries).
We did the same two analyses for adverse pregnancy
outcomes for countries reporting seropositivity and
testing data in both time periods and also included
countries with reported treatment data in 2012. To assess
the validity of the treatment assumption used in updated
2008 estimates, we recalculated proportions using the
2012 treatment data. To describe the burden of syphilis
based on the global distribution of wealth, we stratiﬁed
countries by World Bank income groups.29
We did not perform a formal uncertainty analysis as
there were insuﬃcient data beyond those used in this
analysis to allow for evidence-based calculation of
uncertainty.

Role of the funding source
The funders had no role in the study design, conduct,
analysis, or writing of the manuscript. The corresponding
author had full access to the data and had ﬁnal
responsibility for the decision to submit for publication.
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Figure 1: Estimated numbers of syphilis-associated adverse pregnancy outcomes by WHO region in 2008
and 2012
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c=1

AO_ANC_TNTc + AO_ANC_TTc

N

ΣAO_ANC_NT , where AO_ANC_NT

ΣAO_NOANC , where AO_NOANC

Results
From 2008 to 2012, the number of reporting countries
increased from 88 to 122 for syphilis seropositivity, nine
to 47 for test type, 58 to 106 for testing, and zero (not
reported until 2010) to 74 countries for treatment. Data
availability increased in all WHO regions. In 2012,
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Figure 2: Estimated number of maternal syphilis cases and prevalence by WHO region
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Figure 3: Estimated number of syphilis-associated adverse pregnancy outcome by WHO region
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Figure 4: Estimated number of maternal syphilis (A) and any associated adverse pregnancy outcome (B) for all countries and only countries with data

we estimated that 927 936 pregnant women
(0·66% prevalence) had probable active syphilis
infections, resulting in 350 915 adverse pregnancy
outcomes. These outcomes included 143 100 early fetal
deaths, 44 132 preterm or low birthweight infants,
61 870 neonatal deaths, and 101 813 infected infants
(ﬁgure 1; for the full country dataset see appendix).
The distribution of maternal syphilis infections and
adverse outcomes varied across regions (ﬁgures 2 and 3).
The burden of syphilis in pregnancy was greatest in
Africa, representing 63·1% of global maternal infections
(585 664; 1·68% prevalence) and 64·0% of adverse
outcomes (224 761; 0·66%), and was lowest in Europe,
representing 2·0% of maternal infections (18 437; 0·15%)
and 1·2% of adverse outcomes (4307; 0·04%).
Worldwide in 2012, an estimated 84·6% of pregnant
women with syphilis (779 079 of 927 936 women) attended
antenatal care at least once, of whom 56·4% were not
tested for the infection (439 412 of 779 079); these cases
resulted in 65·1% (228 494) of all 350 915 adverse
outcomes. 5·0% (39 046 of 779 079) of antenatal care
attendees with syphilis were tested but not treated,
e530

resulting in 5·8% (20 304 infants) of all 350 915 adverse
outcomes. Additionally, 38·6% (300 621 of 779 079) of
pregnant women with syphilis who were tested and
treated in antenatal care, but for whom treatment was
ineﬀective (eg, given too late in pregnancy to prevent
an adverse outcome, or given oral treatment rather
than suﬃcient intramuscular doses of benzathine
benzylpenicillin) contributed to 7·0% of all adverse
outcomes (24 711). The 16·0% (148 857 of 927 936) of
pregnant women with syphilis who did not access
antenatal care accounted for 22·1% (77 406 of 350 915) of
adverse outcomes. Overall, 96·6% (896 630 of 927 936)
of maternal syphilis infections and 98·1% (344 474 of
350 916) of adverse outcomes occurred in low-income
and middle-income countries.
From updated 2008 to 2012 estimates, maternal syphilis
infections and adverse outcomes decreased for all
scenarios studied (ﬁgure 4). Using data for all WHO
member countries, from updated 2008 to 2012 estimates,
maternal infections decreased by 37·7% (from
1 488 394 [1·07% prevalence] in 2008 to 927 936 [0·66%]
in 2012) and adverse outcomes decreased by 39·2%

www.thelancet.com/lancetgh Vol 4 August 2016
Downloaded for Anonymous User (n/a) at Aga Khan Hospital from ClinicalKey.com by Elsevier on July 13, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.

Articles

Discussion
This analysis suggests progress in eliminating motherto-child transmission of syphilis, with more than onethird fewer maternal and congenital syphilis infections
from 2008 to 2012. Since the launch of the global
initiative, more countries have introduced universal
syphilis screening in pregnancy, often using rapid
syphilis testing algorithms when laboratory capacity is
limited. More countries have integrated prevention of
mother-to-child transmission of HIV and syphilis into
maternal health programmes. Additionally, surveillance
of antenatal syphilis has improved greatly. India and
Indonesia represented a large proportion of the global
decreases; however, decreased surveillance persisted
even when data for India were excluded.
Despite this positive momentum, syphilis continues to
aﬀect large numbers of pregnant women and result in
substantial perinatal morbidity and mortality. In 2012,
nearly 1 million pregnant women had syphilis infections
and roughly 350 000 had a syphilis-induced adverse
pregnancy outcome despite incremental improvements
in screening and treatment. Most syphilis-induced
pregnancy outcomes were in women who attended
antenatal care, suggesting that these poor outcomes could
have been prevented had recommended testing and

3·50

Sethi et al
Arora et al
UA/GARPR India
Mehta et al
Bala et al

3·00
2·50
2·00
%

(576 784 in 2008 to 350 915 in 2012). Decreases were
notable in southeast Asia (80·9% decrease in maternal
infections; 78·4% decrease in adverse outcomes; ﬁgures 2
and 3). The proportion of pregnant women not tested for
syphilis in antenatal care fell in all regions except Africa
(which increased by 49·0% from 201 547 to 300 246).
When we considered only the 73 countries reporting data
for both 2008 and 2012, we noted a 57·1% decrease in
maternal infections (1 102 261 to 473 030).
We examined data from the ten countries with the
greatest numbers of livebirths to assess their eﬀect on
global and regional estimates (appendix). From updated
2008 to 2012 estimates, the change in seropositivity of
antenatal care attendees in India (from 2·3% to 0·4%)
and Indonesia (from 5·8% to 1·2%) resulted in
489 621 fewer maternal infections and 180 107 fewer
adverse outcomes. India alone accounted for 65·8% of
the global diﬀerence in maternal infections and 64·4% of
adverse outcomes between updated 2008 and 2012
estimates.
Excluding India in reanalysis in updated 2008 and 2012
estimates resulted in a decrease in maternal infections by
18·1% (from 1 059 327 to 867 924 cases) and in adverse
outcomes by 17·8% (401 098 to 329 683 cases; ﬁgure 4).
Countries with data available for both updated 2008 and
2012 estimates had a 38·6% decrease in maternal
infections (from 673 194 to 413 018) and 34·7% decrease
in adverse outcomes (from 56 781 to 37 094). Even if we
assumed the higher treatment values reported in 2012
had also occurred in 2008, adverse outcomes still fell by
more than 20%.

1·50
1·00
0·50
0
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Year

Figure 5: Prevalence of syphilis in pregnant women in India from various sources, 1996–201233–36
UA/GARPR=Universal Access and Global AIDS Response Progress Reporting.

treatment been done. Women and infants in low-income
and middle-income countries suﬀered disproportionately,
and progress in Africa was especially slow.
Our data suggested improvement in coverage of
antenatal syphilis screening and treatment from 2008 to
2012 in most regions worldwide. Nonetheless, many
countries were far from achieving the global programme
targets (at least 95% screening in pregnant women and
95% treatment in women testing positive).30,31 Although
more than three-quarters of pregnant women with
syphilis in 2012 had at least one antenatal care visit,
more than half of these women either did not receive
syphilis testing or received inadequate treatment
to prevent congenital syphilis. These systemic
inadequacies in antenatal care led to nearly 80% of
global congenital syphilis cases (nearly 275 000 events).
This shortcoming is a failure of the public health system
and a clarion call for improving the quality of antenatal
care services.
Global monitoring is improving, with many more
countries reporting data for each of the three core
indicators in 2012 than in 2008. However, 41% of
countries had not reported syphilis seropositivity data,
45% had not reported testing coverage, and 62% had not
reported treatment coverage through the UA/GARPR
system. Increased eﬀorts are needed to strengthen
surveillance and monitoring for the elimination of
mother-to-child transmission of syphilis.12,32,33
Our analysis has limitations. First, the syphilis
seropositivity datapoint reported by India and used in the
updated 2008 estimates might have been spuriously
high. Three consecutive lower values in UA/GARPR and
a scientiﬁc literature review from India on syphilis
prevalence in pregnancy supports this possibility
(ﬁgure 5).33–36 Two studies in India suggest decreases in
syphilis in pregnancy occurred before 2007. Sethi and coauthors33 noted that the prevalence of syphilis in
pregnancy in a tertiary health-care centre in northern
India decreased from 3·0% in 1996 to 0·84% in 2005.
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They attributed the decrease to educating women on
the risks of syphilis in antenatal care, monitoring
management of sexually transmitted infections, and
more widespread use of over-the-counter antibiotics. In
another study, Arora and colleagues34 suggested that
targeted interventions for female sex workers
implemented by the National AIDS Control Organization
and the Avahan Project beginning in 1995 had reduced
the prevalence of syphilis in young pregnant women
from 1·3% in 2003 to 0·4% in 2007. Additionally,
although no peer-reviewed scientiﬁc literature on
Indonesia reported syphilis seropositivity in antenatal
care attendees, the metadata for the UA/GARPR
datapoints suggested that syphilis surveillance in
antenatal care settings has expanded since 2008. The
2008 data were from a pilot project to increase screening
for HIV and syphilis in antenatal care in three provinces,
whereas the 2009 data represented an expanded pilot in
ﬁve provinces. Selected for high HIV prevalence, these
provinces might have a higher prevalence of syphilis
than the national average. Such challenges in obtaining
accurate and nationally representative data are unlikely
to be unique to India and Indonesia.
Second, although completeness of reporting of syphilis
seropositivity in antenatal care attendees through the
UA/GARPR system improved from 2008 to 2012, two
populous countries—Pakistan and the USA—did not
report to WHO during this period. Pakistan does not
currently have a policy of universal syphilis screening in
antenatal care, so nationally representative, routinely
collected data are unavailable. One local study of syphilis
seropositivity in antenatal care attendees in Karachi,
Pakistan, reported 0·9%, which is substantially greater
than the regional mean (0·2%) for the eastern
Mediterranean region.37 The USA did not report antenatal
syphilis data to UA/GARPR, but the US national case
reporting system in 2012 recorded 659 fewer congenital
syphilis cases than our 2012 estimates of adverse
pregnancy outcomes.38 This discrepancy is not substantial
enough to have had an important eﬀect on global or
regional estimates.
Third, the test type used to deﬁne positivity was
unavailable for one-quarter of syphilis seropositivity
values. Although we adjusted for test type to account for
this, this paucity of data increases the uncertainty of our
estimates. Similar data quality issues likely exist for other
datapoints underlying this modelling exercise, and might
aﬀect our estimates. We hope that future rounds of
estimates will be able to better explore ways to capture
this uncertainty.
Finally, interpretation of trends in treatment coverage
is diﬃcult because we did not have country-reported data
for 2008, and relied on regional treatment assumptions.
For example, in Africa, although we are conﬁdent that
screening decreased regionally from 2008 to 2012, we
cannot be certain that treatment of maternal syphilis
worsened over time.
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In summary, these new global estimates of maternal
and congenital syphilis suggest decreases from 2008 to
2012 worldwide and across most WHO regions. However,
our ﬁndings also suggest that untreated maternal syphilis
remains a substantial cause of preventable perinatal
morbidity and mortality. Progress was especially limited
in Africa, the region with the greatest congenital syphilis
burden. Improving access to and the quality of early
antenatal care, increasing syphilis testing at ﬁrst
antenatal care visit, ensuring adequate and prompt
treatment for infected women and their partners, and
expanding programmes of targeted interventions for
high-risk groups are necessary to improve control of the
elimination of mother-to-child transmission of syphilis.
Additionally, nationally representative data on the three
core indicators are important for understanding global,
regional, and country-level progress in eliminating this
old, but still important, public health problem.
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